CoChat
Sign Up
Cited by 61

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

ECM-targeting bacteria enhance chemotherapeutic drug efficacy by lowering IFP in tumor mouse models

Kim, Ji-Sun, Park, Jam-Eon, Choi, Seung-Hyeon, Kang, Se Won, Lee, Ju Huck, Lee, Jung-Sook, Shin, Minsang, Park, Seung-Hwan·2023·Journal of Controlled Release
DOI 10.1016/j.jconrel.2023.02.001
Open this paper in CoChat — free account

Abstract

Bacterial cancer therapies aim to manipulate bacteria to effectively deploy therapeutic payloads to tumors. Attenuated bacteria alone often cannot eradicate solid tumors. Attenuated Salmonella can be engineered to deliver cytotoxic drugs to either trigger an immune response or increase antitumor efficacy when combined with chemotherapeutic drugs. However, the extracellular matrix (ECM) surrounding cancer cells forms a barrier that often limits the ability of chemotherapeutic and cytotoxic drugs to penetrate and eliminate tumors. To overcome this limitation, we developed a strategy to combine chemotherapy with an attenuated Salmonella typhimurium strain engineered to secrete HysA protein (from Staphylococcus aureus; Hyaluronidase, HAase) in tumors. The engineered Salmonella effectively degraded hyaluronan (HA), which is a major ECM constituent in tumors, and suppressed tumor growth in mouse models of pancreatic adenocarcinoma (ASPC-1) and breast cancer (4T1). Furthermore, it prolonged survival when combined with chemotherapeutic drugs (doxorubicin or gemcitabine). Upon bacterial colonization, the HAase-mediated ECM degradation decreased interstitial fluid pressure (IFP) in the tumor microenvironment. Additionally, HA degradation using HAase-expressing bacteria in vivo led to decreased binding to the receptor, CD44, expressed in tumors. This may modulate proliferation- and apoptosis-related signal pathways. Therefore, ECM-targeting bacteria can be used as a synergistic anticanc…

Overview

Integrity signals

Registry

Crossref · 10.1016/j.jconrel.2023.02.001

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Research works printed but not linked: 53

  1. Wang, 2018, Learning from Clostridium novyi -NT: how to defeat cancer, J. Canc. Res. Ther., 14, 1, 10.4103/0973-1482.204841 · DOI
  2. Selvanesan, 2022, Listeria delivers tetanus toxoid protein to pancreatic tumors and induces cancer cell death in mice, Sci. Transl. Med., 14, eabc1600, 10.1126/scitranslmed.abc1600 · DOI
  3. Zhao, 2005, Tumor-targeting bacterial therapy with amino acid auxotrophs of GFP-expressing Salmonella typhimurium, Proc. Natl. Acad. Sci. U. S. A., 102, 755, 10.1073/pnas.0408422102 · DOI
  4. Zheng, 2017, Two-step enhanced cancer immunotherapy with engineered Salmonella typhimurium secreting heterologous flagellin, Sci. Transl. Med., 9, eaak9537, 10.1126/scitranslmed.aak9537 · DOI · Paper page
  5. Jiang, 2013, Engineering of bacteria for the visualization of targeted delivery of a cytolytic anticancer agent, Mol. Ther., 21, 1985, 10.1038/mt.2013.183 · DOI
  6. Jiang, 2010, Inhibition of tumor growth and metastasis by a combination of Escherichia coli-mediated cytolytic therapy and radiotherapy, Mol. Ther., 18, 635, 10.1038/mt.2009.295 · DOI
  7. Zhu, 2011, Antitumor effect of sFlt-1 gene therapy system mediated by Bifidobacterium infantis on Lewis lung cancer in mice, Cancer Gene Ther., 18, 884, 10.1038/cgt.2011.57 · DOI
  8. Tan, 2022, Targeting of pancreatic cancer cells and stromal cells using engineered oncolytic Salmonella typhimurium, Mol. Ther., 30, 662, 10.1016/j.ymthe.2021.08.023 · DOI
  9. Chorobik, 2013, Salmonella and cancer: from pathogens to therapeutics, Acta Biochim. Pol., 60, 10.18388/abp.2013_1984 · DOI
  10. Toso, 2002, Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma, J. Clin. Oncol., 20, 142, 10.1200/JCO.2002.20.1.142 · DOI
  11. Murakami, 2018, Tumor-targeting Salmonella typhimurium A1-R promotes tumoricidal CD8+ T cell tumor infiltration and arrests growth and metastasis in a syngeneic pancreatic-cancer orthotopic mouse model, J. Cell. Biochem., 119, 634, 10.1002/jcb.26224 · DOI
  12. Hiroshima, 2013, Comparison of efficacy of Salmonella typhimurium A1-R and chemotherapy on stem-like and non-stem human pancreatic cancer cells, Cell Cycle, 12, 2774, 10.4161/cc.25872 · DOI
  13. Song, 2004, ppGpp-dependent stationary phase induction of genes on Salmonella pathogenicity island 1, J. Biol. Chem., 279, 34183, 10.1074/jbc.M313491200 · DOI
  14. Zhao, 2006, Targeted therapy with a Salmonella typhimurium leucine-arginine auxotroph cures orthotopic human breast tumors in nude mice, Cancer Res., 66, 7647, 10.1158/0008-5472.CAN-06-0716 · DOI
  15. Nguyen, 2010, Genetically engineered Salmonella typhimurium as an imageable therapeutic probe for cancer, Cancer Res., 70, 18, 10.1158/0008-5472.CAN-09-3453 · DOI
  16. Kim, 2015, Salmonella typhimurium suppresses tumor growth via the pro-inflammatory cytokine interleukin-1β, Theranostics., 5, 1328, 10.7150/thno.11432 · DOI
  17. Min, 2008, Quantitative bioluminescence imaging of tumor-targeting bacteria in living animals, Nat. Protocols., 3, 629, 10.1038/nprot.2008.32 · DOI
  18. Lee, 2004, Endostatin gene therapy delivered by Salmonella choleraesuis in murine tumor models, J. Gene Med., 6, 1382, 10.1002/jgm.626 · DOI · Paper page
  19. Park, 2016, RGD peptide cell-surface display enhances the targeting and therapeutic efficacy of attenuated Salmonella-mediated cancer therapy, Theranostics., 6, 1672, 10.7150/thno.16135 · DOI
  20. Badie, 2021, Use of Salmonella bacteria in cancer therapy: direct, drug delivery and combination approaches, Front. Oncol., 11, 10.3389/fonc.2021.624759 · DOI
  21. Chen, 2017, Modulation of Salmonella tumor-colonization and intratumoral anti-angiogenesis by triptolide and its mechanism, Theranostics., 7, 2250, 10.7150/thno.18816 · DOI
  22. Jia, 2007, Tumor-targeting Salmonella typhimurium improves cyclophosphamide chemotherapy at maximum tolerated dose and low-dose metronomic regimens in a murine melanoma model, Int. J. Cancer, 121, 666, 10.1002/ijc.22688 · DOI
  23. Kawaguchi, 2018, Tumor targeting Salmonella typhimurium A1-R in combination with gemcitabine (GEM) regresses partially GEM-resistant pancreatic cancer patient-derived orthotopic xenograft (PDOX) nude mouse models, Cell Cycle, 17, 2019, 10.1080/15384101.2018.1480223 · DOI
  24. Lee, 2005, Systemic administration of attenuated Salmonella choleraesuis carrying thrombospondin-1 gene leads to tumor-specific transgene expression, delayed tumor growth and prolonged survival in the murine melanoma model, Cancer Gene Ther., 12, 175, 10.1038/sj.cgt.7700777 · DOI
  25. Forbes, 2018, White paper on microbial anti-cancer therapy and prevention, J. Immunoth. Cancer., 6, 78, 10.1186/s40425-018-0381-3 · DOI
  26. Lin, 2021, Bacterial-based cancer therapy: an emerging toolbox for targeted drug/gene delivery, Biomaterials., 277, 10.1016/j.biomaterials.2021.121124 · DOI
  27. Provenzano, 2012, Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma, Cancer Cell, 21, 418, 10.1016/j.ccr.2012.01.007 · DOI · Paper page
  28. Min, 2008, Noninvasive real-time imaging of tumors and metastases using tumor-targeting light-emitting Escherichia coli, Mol. Imaging Biol., 10, 54, 10.1007/s11307-007-0120-5 · DOI
  29. Sironen, 2011, Hyaluronan in human malignancies, Exp. Cell Res., 317, 383, 10.1016/j.yexcr.2010.11.017 · DOI
  30. Kultti, 2012, Therapeutic targeting of hyaluronan in the tumor stroma, Cancers., 4, 873, 10.3390/cancers4030873 · DOI
  31. Erkan, 2012, The role of stroma in pancreatic cancer: diagnostic and therapeutic implications, Nat. Rev. Gastroenterol., 9, 454, 10.1038/nrgastro.2012.115 · DOI · Paper page
  32. Jacobetz, 2013, Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer, Gut., 62, 112, 10.1136/gutjnl-2012-302529 · DOI · Paper page
  33. Turley, 2002, Signaling properties of hyaluronan receptors, J. Biol. Chem., 277, 4589, 10.1074/jbc.R100038200 · DOI
  34. Chen, 2018, The biology and role of CD44 in cancer progression: therapeutic implications, J. Hematol. Oncol., 11, 64, 10.1186/s13045-018-0605-5 · DOI · Paper page
  35. Garin, 2007, CD44 variant DNA vaccination with virtual lymph node ameliorates experimental autoimmune encephalomyelitis through the induction of apoptosis, J. Neurol. Sci., 258, 17, 10.1016/j.jns.2007.01.079 · DOI
  36. Rajasagi, 2010, Anti-CD44 induces apoptosis in T lymphoma via mitochondrial depolarization, J. Cell. Mol. Med., 14, 1453, 10.1111/j.1582-4934.2009.00909.x · DOI
  37. Messina, 2016, Identification and characterization of a bacterial hyaluronidase and its production in recombinant form, FEBS Lett., 590, 2180, 10.1002/1873-3468.12258 · DOI
  38. Hart, 2009, Genotypic and phenotypic assessment of hyaluronidase among type strains of a select group of Staphylococcal species, Int. J. Microbiol., 2009, 10.1155/2009/614371 · DOI
  39. Uthaman, 2016, Preparation of engineered Salmonella typhimurium-driven hyaluronic-acid-based microbeads with both chemotactic and biological targeting towards breast cancer cells for enhanced anticancer therapy, Adv. Healthc. Mater., 5, 288, 10.1002/adhm.201500556 · DOI
  40. Ebelt, 2020, Hyaluronidase-expressing Salmonella effectively targets tumor-associated hyaluronic acid in pancreatic ductal adenocarcinoma, Mol. Cancer Ther., 19, 706, 10.1158/1535-7163.MCT-19-0556 · DOI
  41. Liu, 2022, Comparison of anticancer activities and biosafety between Salmonella enterica serovar typhimurium ΔppGpp and VNP20009 in a murine cancer model, Front. Microbiol., 13
  42. Tan, 2022, Targeting of pancreatic cancer cells and stromal cells using engineered oncolytic Salmonella typhimurium, Mol. Ther., 30, 662, 10.1016/j.ymthe.2021.08.023 · DOI
  43. Yi, 2020, Bacteria-triggered tumor-specific thrombosis to enable potent photothermal immunotherapy of cancer, Sci. Adv., 6, eaba3546, 10.1126/sciadv.aba3546 · DOI
  44. Farrell, 1995, Cloning, nucleotide sequence determination and expression of the Staphylococcus aureus hyaluronate lyase gene, FEMS Microbiol. Lett., 130, 81
  45. Le, 2011, Engineering and visualization of bacteria for targeting infarcted myocardium, Mol. Ther., 19, 951, 10.1038/mt.2011.25 · DOI
  46. Dorfman, 1948, A turbidimetric method for the assay of hyaluronidase, J. Biol. Chem., 172, 367, 10.1016/S0021-9258(19)52721-1 · DOI
  47. Ozerdem, 2005, A simple method for measuring interstitial fluid pressure in cancer tissues, Microvasc. Res., 70, 116, 10.1016/j.mvr.2005.07.003 · DOI
  48. Schwertfeger, 2015, Hyaluronan, inflammation, and breast cancer progression, Front. Immunol., 6, 236, 10.3389/fimmu.2015.00236 · DOI
  49. Chanmee, 2016, Hyaluronan: a modulator of the tumor microenvironment, Cancer Lett., 375, 20, 10.1016/j.canlet.2016.02.031 · DOI
  50. Hyun, 2021, Engineered attenuated Salmonella typhimurium expressing neoantigen has anticancer effects, ACS Synth. Biol., 10, 2478, 10.1021/acssynbio.1c00097 · DOI
  51. Hingorani, 2017, HALO 202: randomized phase II study of PEGPH20 plus nab-paclitaxel/gemcitabine versus nab-paclitaxel/gemcitabine in patients with untreated, metastatic pancreatic ductal adenocarcinoma, J. Clin. Oncol., 36
  52. Petrelli, 2010, Targeted delivery for breast cancer therapy: the history of nanoparticle-albumin-bound paclitaxel, Expert. Opin. Pharmacother., 11, 1413, 10.1517/14656561003796562 · DOI
  53. Benitez, 2011, Targeting hyaluronidase for cancer therapy: antitumor activity of sulfated hyaluronic acid in prostate cancer cells, Cancer Res., 71, 4085, 10.1158/0008-5472.CAN-10-4610 · DOI

Cited by

Sorted by citations

See all 61

Metadata

Authors
Kim, J.-S., Park, J.-E., Choi, S.-H., Kang, S. W., Lee, J. H., Lee, J.-S., Shin, M., & Park, S.-H.
Venue
Journal of Controlled Release
Publisher
Elsevier BV
Published
2023-03
Volume
355
Pages
199-210
ISSN
0168-3659
DOI
10.1016/j.jconrel.2023.02.001
Cited by
61
References
3
Language
en
Licence
Funders
  • Ministry of Science, ICT and Future Planning (NRF-2021M3H9A1037439, NRF-2014M3A9B5073747)
  • National Research Foundation of Korea
  • Korea Research Institute of Bioscience and Biotechnology (KGM5232221, NTIS1711170602)
  • Korea Ministry of Trade Industry and Energy (20009412)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review